abatacept

Ligand id: 6891

Name: abatacept

IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: abatacept

Classification
Compound class Antibody
Ligand families/groups Immune checkpoint modulators
Approved drug? Yes (FDA (2005), EMA (2005))
International Nonproprietary Names
INN number INN
8495 abatacept
Synonyms
BMS-188667 | CTLA4-IgG4m | Orencia® | RG-1046 | RG-2077
Database Links
Specialist databases
IMGT/mAb-DB 212
Other databases
ChEMBL Ligand CHEMBL1201823 (Hs)
DrugBank Ligand DB01281
GtoPdb PubChem SID 178103473
PubChem SID 135355129
Search PubMed clinical trials abatacept
Search PubMed titles abatacept
Search PubMed titles/abstracts abatacept
Wikipedia Abatacept
Comments
Abatacept is a recombinant protein fusing the extracellular domain of human cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) to the modified Fc (hinge, CH2, and CH3 domains) portion of human immunoglobulin G1 (IgG1) [3]. In essence, abatacept is a CTLA-4 mimetic, that enhances CTLA-4's inhibitory signal to T cells, thereby down-modulating T cell mediated inflammation.